Symptoms reported in those who report: (A) <4 weeks since symptom onset; (B) 4–8 weeks since symptoms onset; (C) 8–12 weeks since symptoms onset; (D) >12 weeks since symptoms onset
| <4 weeks, n=270 | 4–8 weeks, n=494 | 8–12 weeks, n=641 | >12 weeks, n=1865 | P value | |
| Gender | |||||
| Female | 214 (79.3) | 387 (78.3) | 506 (78.9) | 1440 (77.2) | 0.714 |
| Male | 52 (19.3) | 98 (19.8) | 131 (20.4) | 403 (21.6) | |
| Age (years) | |||||
| 17 or under | 0 (0.0) | 1 (0.2) | 1 (0.2) | 4 (0.2) | |
| 18–24 | 9 (3.3) | 8 (1.6) | 8 (1.2) | 30 (1.6) | |
| 24–34 | 40 (14.8) | 65 (13.2) | 82 (12.8) | 220 (11.8) | |
| 35–44 | 64 (23.7) | 123 (24.9) | 159 (24.8) | 427 (22.9) | 0.038 |
| 45–54 | 91 (33.7) | 168 (34.0) | 222 (34.6) | 630 (33.8) | |
| 55–64 | 51 (18.9) | 96 (19.4) | 137 (21.4) | 402 (21.6) | |
| 65–74 | 13 (4.8) | 22 (4.5) | 28 (4.4) | 128 (6.9) | |
| 75 or older | 2 (0.7) | 10 (2.0) | 4 (0.6) | 24 (1.3) | |
| Ethnicity | |||||
| White | 242 (89.6) | 457 (92.5) | 609 (95.0) | 1735 (93.0) | |
| Black, African, black British or Caribbean | 5 (1.9) | 7 (1.4) | 6 (0.9) | 23 (1.2) | |
| Asian or Asian British | 15 (5.6) | 17 (3.4) | 12 (1.9) | 48 (2.6) | 0.089 |
| Mixed or multiple ethnic groups | 3 (1.1) | 7 (1.4) | 10 (1.6) | 36 (1.9) | |
| Symptoms | |||||
| Breathing problems | 246 (91.1) | 460 (93.1) | 596 (93.0) | 1707 (91.5]) | 0.47 |
| Changes in mood, or anxiety or depression | 93 (34.4) | 206 (41.7) | 266 (41.5) | 842 (45.1) | 0.006 |
| Cough | 135 (50.0) | 221 (44.7) | 275 (42.9) | 752 (40.3) | 0.013 |
| Extreme tiredness/fatigue/lack of energy | 216 (80.0) | 406 (82.2) | 535 (83.5) | 1568 (84.1) | 0.338 |
| Hair loss | 10 (3.7) | 24 (4.9) | 61 (9.5) | 248 (13.3) | <0.001 |
| Loss of appetite or weight loss | 70 (25.9) | 126 (25.5) | 126 (19.7) | 430 (23.1) | 0.069 |
| Loss of taste or smell (anosmia) | 120 (44.4) | 152 (30.8) | 172 (26.8) | 488 (26.2) | <0.001 |
| Muscle weakness or joint stiffness | 118 (43.7) | 235 (47.6) | 315 (49.1) | 984 (52.8) | 0.012 |
| Nightmares or flashbacks | 25 (9.3) | 60 (12.1) | 69 (10.8) | 273 (14.6) | 0.012 |
| Problems with mental abilities including anxiety/depression | 79 (29.3) | 192 (38.9) | 279 (43.5) | 950 (50.9) | <0.001 |
| Sleep problems | 112 (41.5) | 233 (47.2) | 296 (46.2) | 887 (47.6) | 0.196 |
| Symptoms of PTSD | 35 (13.0) | 74 (15.0) | 111 (17.3) | 352 (18.9) | 0.037 |
| Number of coexisting symptoms | 4.7±2.1 | 4.8±2.3 | 4.8±2.3 | 5.1±2.4 | 0.005 |
| Treatment during acute phase of virus | |||||
| Self-treatment at home | 229 (84.8) | 404 (81.8) | 575 (89.7) | 1652 (88.6) | <0.001 |
| Hospitalised (but not intensive care) | 32 (11.9) | 68 (13.8) | 52 (8.1) | 160 (8.6) | |
| Hospitalised (intensive care) | 9 (3.3) | 22 (4.5) | 14 (2.2) | 53 (2.8) |
Data are presented as n (%) or mean (SD). P values of <0.05 are for χ2 or one-way analysis of variance as appropriate. Where numbers do not total 100%, missing values are due to questions unanswered by participant. Changes of mood are taken to indicate a negative change in mood (ie, more anxious, more depressed, etc).
PTSD, post-traumatic stress disorder.